Scynexis Inc 's Comment on Competition and Industry Peers
SCY-247 and future product candidates compete with antifungal drugs marketed by large pharmaceutical, biotechnology, specialty pharmaceutical, and generic drug companies with greater resources. Key antifungal products include Noxafil® (posaconazole) by Merck, Cresemba® (isavuconazole) by Astellas, Vivjoa® (oteseconazole) by Mycovia Pharmaceuticals, Inc., Diflucan® (fluconazole) by Pfizer, Terazol (terconazole) by Jannsen, and Gynazole (butoconazole) by Perrigo. Olorofim (F901318) is under development by F2G Limited. The commercial success of these antifungal drugs depends on factors such as efficacy, safety, convenience, outpatient use, generic competition, and reimbursement availability. Although SCY-247 has unique features that may support premium pricing, its market opportunity could be limited if competitors introduce safer, more effective, more convenient, or less expensive products or achieve regulatory approval more rapidly.
Amphastar Pharmaceuticals Inc's business model revolves around developing, manufacturing, and marketing specialty pharmaceutical products. The company focuses on niche markets and primarily produces finished dosage form and active pharmaceutical ingredients (APIs) for injectable, inhalation, and intranasal delivery systems. Amphastar aims to provide innovative and cost-effective solutions for complex therapeutic needs, while maintaining regulatory compliance and ensuring the highest standard of quality.
Atea Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing antiviral therapeutics to combat infectious diseases. Their business model revolves around identifying and advancing novel drug candidates that target specific viral mechanisms and inhibit their replication. This includes conducting preclinical and clinical trials, engaging in strategic partnerships, and ultimately bringing effective antiviral treatments to market.
Sources:
Scynexis Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Scynexis Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
